Featured 13F manager
Johnson & Johnson
New Brunswick, NJ 6 processed 13Fs on this site · 2025 Q3–2026 Q2
- $799M
- 15 Positions
- 2026 Q2
- +22.5% QoQ
- Top 5 88.8%
Johnson & Johnson files a Form 13F. The latest book is 2026 Q2 at $799M, up 22.5% QoQ, led by Protagonist Therapeutics, Nanobiotix, and Meiragtx.
Portfolio
top 5 88.8% · top 10 98.4%
- PTGX - Protagonist Therapeutics 37.6%
- NBTX - Nanobiotix 26.6%
- MGTX - Meiragtx 11.2%
- RAPP - Rapport Therapeutics 9.3%
- CTNM - Contineum Therapeutics · CL A 4.1%
- Legend Biotech 2.9%
- CVRX — 2.6%
- Xencor 1.5%
- CBRS - Cerebras Systems · CL A 1.5%
- FATE - Fate Therapeutics 1.1%
- PRCT - Procept Biorobotics 1.0%
- NMRA - Neumora Therapeutics 0.4%
- Other 0.2%
AUM over time
Book
| PTGX - Protagonist Therapeutics | 38.57% | Hold | 2,449,183 | $87.34 | $214M | — | — |
| NBTX - Nanobiotix S A | 23.44% | Hold | 5,623,816 | $23.12 | $130M | — | — |
| RAPP - Rapport Therapeutics | 9.76% | Hold | 1,784,517 | $30.34 | $54M | — | — |
| MGTX - MeiraGTx | 9.52% | Hold | 6,641,064 | $7.95 | $53M | — | — |
| CVRX — | 5.15% | Reduce −1.9% | 4,024,861 | $7.10 | $29M | −78,569 | −$5M |
| CTNM - Contineum Therapeutics · CL A | 4.08% | Hold | 1,979,173 | $11.43 | $23M | — | — |
| Legend Biotech | 3.19% | Hold | 814,586 | $21.74 | $18M | — | — |
| Xencor | 2.06% | Hold | 748,062 | $15.31 | $11M | — | — |
| PRCT - Procept BioRobotics | 2.03% | Hold | 357,939 | $31.46 | $11M | — | — |
| FATE - Fate Therapeutics | 0.60% | Hold | 3,379,064 | $0.9826 | $3M | — | — |
| NMRA - Neumora Therapeutics | 0.60% | Hold | 1,849,445 | $1.79 | $3M | — | — |
| Rallybio | 0.45% | Hold | 3,636,363 | $0.6861 | $2M | — | — |
| LYEL - Lyell Immunopharma | 0.23% | Hold | 41,165 | $30.78 | $1M | — | — |
| Vor Biopharma | 0.13% | Hold | 53,732 | $13.08 | $703K | — | — |
| Nano-X Imaging | 0.08% | Hold | 158,852 | $2.80 | $445K | — | — |
| LAB - Standard BioTools | 0.07% | Hold | 311,967 | $1.28 | $399K | — | — |
| ACET - Adicet Bio | 0.03% | New | 22,779 | $8.42 | $192K | +22,779 | +$192K |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ARWR - Arrowhead Pharmaceuticals | 1.70% | Exit | 0 | $34.49 | $9M | −247,598 | −$9M |
| Adicet Bio | 0.06% | Exit | 0 | $0.8094 | $295K | −364,472 | −$295K |
| BiomX | 0.01% | Exit | 0 | $0.5265 | $51K | −96,866 | −$51K |
| Senseonics | — | Exit | 0 | $0.4394 | $24K | −54,621 | −$24K |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 15 | $799M | +22.5% | 13F-HR | 8/6/2026 | 000090445426000435 |
| 2026 Q1 | 16 | $652M | +17.5% | 13F-HR | 5/13/2026 | 000090445426000280 |
| 2025 Q4 | 17 | $555M | — | RESTATEMENT | 3/18/2026 | 000090445426000192 |
| 2025 Q4 | 17 | $555M | +10.1% | 13F-HR | 2/13/2026 | 000090445426000111 |
| 2025 Q3 | 20 | $504M | — | RESTATEMENT | 3/18/2026 | 000090445426000190 |
| 2025 Q3 | 20 | $504M | — | 13F-HR | 11/13/2025 | 000090445425000587 |
About
Johnson & Johnson
6 processed 13Fs on this site · 2025 Q3–2026 Q2